Financial Comparison: Cartesian Therapeutics (NASDAQ:RNAC) and ProKidney (NASDAQ:PROK)

ProKidney (NASDAQ:PROK) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.

Earnings & Valuation

This table compares ProKidney and Cartesian Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890,000.00	621.62	-$68.99 million	($0.55)	-3.33
Cartesian Therapeutics	$2.80 million	87.29	-$130.30 million	($5.94)	-1.36

ProKidney has higher earnings, but lower revenue than Cartesian Therapeutics. ProKidney is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for ProKidney and Cartesian Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1	0	1	1	2.67
Cartesian Therapeutics	1	1	5	0	2.57

ProKidney currently has a consensus price target of $12.00, suggesting a potential upside of 555.74%. Cartesian Therapeutics has a consensus price target of $32.60, suggesting a potential upside of 303.47%. Given ProKidney’s stronger consensus rating and higher possible upside, equities analysts clearly believe ProKidney is more favorable than Cartesian Therapeutics.

Volatility and Risk

ProKidney has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

Insider and Institutional Ownership

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 39.8% of ProKidney shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares ProKidney and Cartesian Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProKidney	-10,288.39%	N/A	-27.39%
Cartesian Therapeutics	-8,550.65%	N/A	-29.84%

Summary

ProKidney beats Cartesian Therapeutics on 9 of the 14 factors compared between the two stocks.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.